Highlights in myasthenia gravis from AANEM 2024 include efficacy data on efgartigimod, ravulizumab, zilucoplan, and first-in-class inebilizumab, as well as safety outcomes in pregnancy for eculizumab.

Increased demands from an aging population and pandemic-related supply shortages leave provinces scrambling to allocate ...

The US Food and Drug Administration (FDA) sometimes allows cancer drugs with accelerated approvals to remain on the market ...

First, there were “Ozempic babies.” Now, there is also Ozempic-before-baby. Unplanned pregnancies are still regularly being ...

The first pregnancy guideline updates from the American Thyroid Association since 2017 to emphasize shared decision-making, ...

The US Food and Drug Administration (FDA) has approved obecabtagene autoleucel, or obe-cel (AUTO1, Autolus Therapeutics) for the treatment of relapsed or refractory adult B-cell acute lymphoblastic ...

Individuals at an increased risk of developing rheumatoid arthritis (RA) have a unique gut microbial composition, ...

Higher plasma levels of omega-6 and omega-3 fatty acids are associated with a lower incidence of cancer. However, omega-3 ...

In September this year in Rome, an older woman died, and her daughter spent a week in intensive care after eating a few ...

The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for ...

SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...

PHILADELPHIA — Patients with celiac disease who take an angiotensin receptor blocker (ARB) may experience worse outcomes, ...